Jane Street Group LLC Has $814,000 Position in Xencor, Inc. (NASDAQ:XNCR)

Jane Street Group LLC trimmed its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 79.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 35,437 shares of the biopharmaceutical company's stock after selling 132,994 shares during the period. Jane Street Group LLC owned approximately 0.05% of Xencor worth $814,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Barclays PLC grew its stake in Xencor by 100.7% during the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock worth $3,128,000 after buying an additional 78,066 shares in the last quarter. Prudential Financial Inc. boosted its stake in shares of Xencor by 10.7% in the 4th quarter. Prudential Financial Inc. now owns 70,715 shares of the biopharmaceutical company's stock valued at $1,625,000 after purchasing an additional 6,810 shares in the last quarter. Wellington Management Group LLP acquired a new stake in shares of Xencor in the 4th quarter valued at approximately $632,000. Raymond James Financial Inc. acquired a new stake in shares of Xencor in the 4th quarter valued at approximately $2,329,000. Finally, Principal Financial Group Inc. boosted its stake in shares of Xencor by 16.5% in the 4th quarter. Principal Financial Group Inc. now owns 340,145 shares of the biopharmaceutical company's stock valued at $7,817,000 after purchasing an additional 48,229 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on XNCR shares. Wall Street Zen downgraded shares of Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Barclays cut their target price on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research report on Thursday, May 8th. William Blair initiated coverage on shares of Xencor in a research report on Monday, April 21st. They set an "outperform" rating on the stock. Wells Fargo & Company cut their target price on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Finally, Wedbush reiterated an "outperform" rating and set a $31.00 target price on shares of Xencor in a research report on Wednesday, April 30th. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.50.

Xencor Trading Up 2.5%

Xencor stock traded up $0.19 during mid-day trading on Thursday, hitting $7.74. 1,123,641 shares of the stock were exchanged, compared to its average volume of 659,852. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a 12 month low of $7.16 and a 12 month high of $27.24. The firm's fifty day simple moving average is $9.23 and its two-hundred day simple moving average is $16.32. The stock has a market capitalization of $550.86 million, a price-to-earnings ratio of -2.42 and a beta of 0.99.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm had revenue of $32.73 million for the quarter, compared to the consensus estimate of $23.44 million. During the same quarter in the previous year, the business posted ($1.11) EPS. The firm's revenue for the quarter was up 104.6% compared to the same quarter last year. Analysts forecast that Xencor, Inc. will post -3.68 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Nancy Valente sold 4,616 shares of Xencor stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total value of $50,914.48. Following the completion of the sale, the executive vice president now owns 49,169 shares in the company, valued at $542,334.07. The trade was a 8.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 4.76% of the company's stock.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.